INCORPORATION BY REFERENCE
This report on Form6-K shall be deemed to be incorporated by reference into the registration statements on FormS-8 (Registration Numbers333-203040,333-210810,333-211512,333-213412,333-214843 and333-216883) and FormF-3 (Registration Numbers333-209336,333-211511,333-216882,333-223134 and333-225284) of Ascendis Pharma A/S (“Ascendis” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Annual General Meeting Results
On November 2, 2018, Ascendis held an Extraordinary General Meeting. 27,880,670 ordinary shares of Ascendis (which includes 26,878,454 ordinary shares represented by American Depositary Shares), representing in total 66.33% of the ordinary shares outstanding as of the date of the Extraordinary General Meeting, were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:
Agenda Item 1: Election of Chairman of the Meeting
Ascendis shareholders elected Anders Carstensen as chairman of the meeting.
Agenda Item 2: Election of new Board Member
Ascendis shareholders elected Lars Holtug as a Class II director, with the term for such board member to expire at the Annual General Meeting of the Company to be held in 2020.
Agenda Item 3: Authorization of the Chairman of the meeting
Ascendis shareholders authorized the chairman of the meeting (with a right of substitution) on behalf of the Company to apply to the Danish Business Authority for registration of the resolutions passed and to make any such amendments and supplements to the application and the resolutions, including the Company’s articles of association and these minutes of the general meeting, as may be required as a condition for registration.
